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a  b  s  t  r  a  c  t
Background: Clostridium difﬁcile infections caused by the NAP1/B1/027 strain are more severe,
difﬁcult to treat, and frequently associated with relapses.
Methods: A case–control study was designed to examine a C. difﬁcile infection (CDI) outbreak
over a 12-month period in a Mexican hospital. The diagnosis of toxigenic CDI was conﬁrmed
by  real-time polymerase chain reaction, PCR (Cepheid Xpert C. difﬁcile/Epi).
Results: During the study period, 288 adult patients were evaluated and 79 (27.4%) patients
had  conﬁrmed CDI (PCR positive). C. difﬁcile strain NAP1/B1/027 was identiﬁed in 31 (39%) of
the  patients with conﬁrmed CDI (240 controls were included). Signiﬁcant risk factors for CDI
included any underlying disease (p < 0.001), prior hospitalization (p < 0.001), and antibiotic
(p  < 0.050) or steroid (p < 0.001) use. Laboratory abnormalities included leukocytosis (p < 0.001)
and  low serum albumin levels (p < 0.002). Attributable mortality was 5%. Relapses occurred
in  10% of patients. Risk factors for C. difﬁcile NAP1/B1/027 strain infections included prior
use  of quinolones (p < 0.03).
Risk factors for CDI caused by non-027 strains included chronic cardiac disease (p < 0.05),
chronic renal disease (p < 0.009), and elevated serum creatinine levels (p < 0.003). Deaths and
relapses were most frequent in the 027 group (10% and 19%, respectively).
Conclusions: C. difﬁcile NAP1/BI/027 strain and non-027 strains are established pathogens inour  hospital. Accordingly, surveillance of C. difﬁcile infections is now part of our nosocomial
prevention program.
∗ Corresponding author at: Instituto de Patología Infecciosa y Experime
Jalisco, Mexico.
E-mail address: rayomorﬁn@gmail.com (R. Morﬁn-Otero).
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Nb r a z j i n f e c t d
ntroduction
lostridium difﬁcile infections (CDI) are the leading world-
ide cause of healthcare-associated diarrhea and in some
ountries CDI surpass all other healthcare-associated infec-
ions (HCAI).1 A recent prevalence survey of HCAI conducted
cross 183 hospitals determined that C. difﬁcile was the most
requently reported infectious agent, responsible for 12.1% of
ll HCAI.1
In the United States of America (USA) during 2011, 15,461
DI cases were reported with 24.2% of cases having an onset
uring hospitalization. Incident CDI cases were estimated
o be >450,000 with an estimated >29,000 deaths.2 However,
he emergence of the C. difﬁcile NAP1/B1/027 strain in 2000
hanged the morbidity and mortality rates associated with
DI.3,4
Since 2004, the role of other emergent C. difﬁcile strains
ausing human disease has expanded. These strains are
erived from 39 different ribotypes and some C. difﬁcile strains
ave been found to be toxin A-negative but toxin B-positive,5
nd 027 strain was the second most common isolate respon-
ible for CDI.6 Ribotype 078 was reported to have an increased
revalence,7 and ribotype 244 seems to cause more  severe
isease with higher mortality rates than rates associated
ith ribotype 027.8,9 The prevalence of other ribotypes now
ppears to surpass that of 027, including ribotypes 037, 018,
nd 078.10–12
Epidemiologic research of CDI resulting from infections
ith diverse C. difﬁcile strains, including strain NAP1/B1/027
n developing countries, is expanding and includes data
egarding hospital epidemiology, clonal spread, and dissem-
nation across the respective countries.13–16
The present study reports on a 12-month evaluation of a
DI outbreak caused by different C. difﬁcile strains including
he NAP1/BI/027 strain.
ethods
etting,  study  design,  and  study  population
he outbreak described in this report occurred at the Hospital
ivil de Guadalajara Fray Antonio Alcalde, an 899-bed tertiary
are teaching hospital located in the city of Guadalajara, the
econd largest city in Mexico.
This was a case–control study of adult patients with
ospital-onset CDI presenting between December 2013 and
ecember 2014. During the study period 288 adult patients
ere evaluated and all patients had diarrhea deﬁned as the
assage of ≥3 unformed stools (Bristol scale type 5–7) within
4 or 48 h after admission.17 Case patients were deﬁned as
hose with a ﬁrst episode of nosocomial CDI.
lostridium  difﬁcile  toxin  identiﬁcation
tarting in April 2014, all stool samples were tested for
. difﬁcile toxins using real-time polymerase chain reaction
PCR) (Cepheid Xpert C. difﬁcile/Epi, Cepheid, Sunnyvale CA)
o identify toxin-producing C. difﬁcile strains, including strain
AP1/B1/027. Prior to the availability of PCR-based diagnostic 0 1 6;2 0(1):8–13 9
approaches all diarrhea specimens were tested by enzyme
immunoassay (Meridian Bioscience, Cincinnati, OH, USA). All
positive specimens were saved for future testing. All stool
specimens were stored at 4◦ C for ﬁve days, and then frozen
at −70◦ C. After PCR retesting, only positive samples were
included in the ﬁnal analysis.
Control  patients
Patients without diarrhea or a positive CDI test were selected
at the same time and ward that CDI patients were identi-
ﬁed. Control patients were randomly selected across the study
period. Control patients were matched to case patients at a 3:1
ratio.
Deﬁnitions
Previous hospitalization was deﬁned as a hospital stay six
weeks prior to the onset of diarrhea. Recent antibiotic therapy
and steroid use were deﬁned as exposure to these medicines
six weeks prior to diarrhea onset.
Clinical  severity  score  assessment  and  outcome
Patients were clinically evaluated for disease severity using
the SHEA/IDSA deﬁnitions of mild, moderate, or severe dis-
ease. Serum creatinine levels were included in the deﬁnition
of severe disease.18 In addition, age >60 years, fever >38.3 ◦C,
and a WBC  count >15,000 were used to further deﬁne clinically
severe disease.19 Patients with >2 ﬁndings were considered to
have severe disease.
A poor outcome was deﬁned as death within 14 days after
CDI diagnosis. Favorable outcome was deﬁned by survival 14
days after CDI diagnosis. Relapse was deﬁned as a second
episode of diarrhea after adequate response to therapy.
Therapy  and  follow-up
Therapy for CDI was administered for 10 days after an ade-
quate response to treatment was achieved (deﬁned as a 50%
reduction of loose stools after 24 h of therapy, continuous
reduction after 48 h of treatment, and no diarrhea after 72 h
of treatment). All patients discharged where followed via tele-
phone every 30 days.
Statistical  analysis
The data generated were coded, entered, validated, and ana-
lyzed using the Statistical Package for Social Science (SPSS),
version 22.0. Univariate analyses were used to describe sig-
niﬁcant variables among cases and controls and among
individuals infected with strain 027 and individuals infected
with non-027 strains. P-values were calculated using the Chi-
squared test or the Fisher’s exact test for categorical variables
and the Student’s t-test or Wilcoxon rank-sum test for con-
tinuous variables. A p-value ≤0.05 was considered statistically
signiﬁcant. Multivariate analysis: logistic regression analysis
was carried out considering CDI as dependent variable and
clinical and demographic data as independent variables.
10  b r a z j i n f e c t d i s . 2 0 1 6;2  0(1):8–13
Table 1 – Characteristics of CDI patients and controls, severity, outcomes, relapses, and clinical aspects of patients
infected with 027 and non-027 strains.
Parameters CDI patients (n = 79)
n  (%)
Controls (n = 240)
n (%)







18–30 23 (29.1) 62 (25.8) 0.28 7 (23) 16 (34) 0.22
31–50 24 (30.4) 88 (36.7) 0.15 11 (35) 13 (27) 0.29
51–65 21 (26.6) 53 (22.1) 0.20 10 (32) 12 (25) 0.32
>65 11 (13.9) 37 (15.4) 0.38 3 (10) 7 (14) 0.39
Gender
Male 51 (64.5) 148 (61.7) 0.32 21 (67.7) 30 (62.5) 0.40
Female 28 (35.5) 92 (38.3) 0.32 10 (32.3) 18 (37.5) 0.40
Underlying disease
Any 73  (92.4) 170 (70.8) <0.001 27 (87.1) 46 (95.6) 0.15
Malignancy 11 (13.9) 18 (7.5) 0.142 6 (19.3) 5 (10.4) 0.21
Diabetes mellitus 20 (25.3) 51 (21.3) 0.27 5 (16.1) 15 (31.3) 0.10
Chronic cardiac disease 22 (27.8) 49 (20.4) 0.112 5 (16.1) 17 (35.4) 0.05
Chronic hepatic disease 2 (2.5) 5 (2.0) 0.55 0 2 (4.2) 0.36
Previous episode of
pneumonia
16  (20.2) 16 (6.7) 0.005 5 (16.1) 11 (22.9) 0.33
Chronic renal disease 23 (29.1) 43 (17.9) 0.027 4 (12.9) 19 (39.6) 0.009
Healthcare-associated exposure
Prior hospitalization 43 (54.4) 57 (23.8) <0.001 20 (64.5) 23 (47.9) 0.11
Prior surgery 44 (55.7) 117 (48.8) 0.173 17 (62.9) 27 (56.3) 0.54
Prior antibiotics
Any 58 (73.4) 150 (62.5) 0.050 23 (74.2) 35 (72.9) 0.55
Betalactams 43 (54.4) 108 (45) 0.155 17 (54.8) 30 (62.5) 0.32
Quinolones 16 (20.3) 31 (12.9) 0.142 9 (39.13) 5 (10.4) 0.03
Clindamycin 10 (12.7) 38 (15.8) 0.313 4 (17.39) 6 (12.5) 0.60
Prior use of acid suppressing medication
Proton pump inhibitors 67 (84.8) 192 (80.0) 0.21 25 (80.65) 42 (87.5) 0.30
H2 blocker 5 (6.3) 18 (7.5) 0.47 1 (3.23) 4 (8.3) 0.34
Prior use of steroids 17 (21.5) 16(6.7) <0.001 8 (25.8) 9 (18.8) 0.31
White blood cells count
>12,000/mm3
37 (46.8) 63 (26.3) <0.001 15 (48.4) 22 (45.8) 0.50
Serum creatinine
≥1.5 mg/dl
22  (27.8) 53 (22.1) 0.20 3 (9.7) 19 (39.6) 0.003
Serum albumin <3 g dl 46 (58.2) 91 (37.9) <0.002 18 (58.1) 28 (58.3) 0.58
Initial Clinical Severity
Score ≥2
69  (87.3) – – 28 (90) 41 (85) 0.39
Outcome
Poor/death 4 (5) – – 3 (10) 1 (2) 0.16
Good/cured 75 (95) – – 28 (90) 47 (98) 0.16
Relapses 8 (10) – 
Results
Study  population
The age range of CDI patients and controls were similar
(Table 1). Patients >65 years of age were the minority in both
groups (Table 1). There was no gender difference between
cases and controls; however, males were more frequently
affected with CDI than females (Table 1). The presence of
any underlying disease was an important risk factor for
acquiring CDI, especially a previous episode of pneumonia
or the presence of chronic renal disease (Table 1). Additional
risk factors associated with CDI included prior hospitaliza-
tion, antibiotic or steroid use, and elevated white blood cell– 6 (19) 2 (4) 0.03
counts (>12,000/mm3) combined with low serum albumin lev-
els (<3 g/dl) (Table 1). Four (5%) patients died in the CDI group
and 8 (10%) relapsed (Table 1). The incidence of CDI was 1.7
per 1000 discharges.
NAP1/B1/027  infections
Strain NAP1/B1/027 was identiﬁed in 31 (39%) patients with
CDI. There were some differences between CDI resulting from
infections with strain 027 and non-027 strains. The presence
of chronic cardiac disease and chronic renal disease were
found to be signiﬁcantly more  frequent in the non-027 group
(Table 1). Although both groups had a similar initial severity
score, more  deaths and relapses were associated with strain
b r a z j i n f e c t d i s . 2 0
Table 2 – Multivariate logistic regression analysis of risk
factors for CDI.
Risk factor OR CI 95% p-value
White blood cells count
>12,000/mm3
2.541 1.414–4.567 0.002
Prior hospitalization 4.029 2.240–7.246 0.001
Serum Albumin <3 g dl 2.026 1.138–3.608 0.016










































Prior use of steroids 5.077 2.203–11.698 0.001
27 infections (Table 1). Additional risk factors associated
ith 027 and non-027 infections were prior use of quinolone
nd abnormal serum creatinine level (>1.5 mg/dl), respectively
Table 1).
Logistic regression analysis included the signiﬁcant risk
actors for CDI prior use of steroids, a previous episode of
neumonia, and prior hospitalization (Table 2). Also identi-
ed abnormal white blood cell count and low serum albumin
evels as independent risk factors for acquiring CDI (Table 2).
iscussion
he CDI outbreak described in this report occurred following
ntroduction of the C. difﬁcile 027 strain into our hospital by a
atient diagnosed in December 2013. This individual had had
ultiple healthcare contacts in the USA (including several due
o diarrhea) prior to being admitted to our neurosurgical ward.
ntroduction of C. difﬁcile into a hospital will usually develop
nto an outbreak and previous studies have documented out-
reaks following detection of strain 027.3,4,20
Other Latin American countries from Central and South
merica have now described the presence and dissemina-
ion of C. difﬁcile.15,21 The C. difﬁcile dissemination pattern
een in Mexico was similar to that described in hospitals in
he USA and Canada, but different from that of the Euro-
ean Union where C. difﬁcile 027 is not yet as prevalent. The
ppearance, establishment, and dissemination of C. difﬁcile in
exico seemed to occur in large referral hospitals where a high
ercentage of patients admitted had multiple risk factors for
DI.14,22
The presence of a serious underlying disease is a frequent
isk factor for the development of CDI23 and the presence
f any underlying illness (particularly a previous episode of
neumonia) was a signiﬁcant risk factor in patients compared
o controls.
In our population, community acquired pneumonia was
iagnosed most frequently in older patients with comorbidi-
ies including chronic obstructive pulmonary disease. These
atients typically had multiple previous healthcare exposures
ncluding prior hospitalizations allowing for a greater prob-
bility of acquiring C. difﬁcile. Because current guidelines of
ur hospital recommend administration of quinolones as
mpiric treatment for pneumonia24 this patient group had
een exposed to this drug.A frequent risk factor in our study included patients with
hronic renal disease. Since our hospital is a regional center
or the diagnosis and care of patients in need of renal replace-
ent therapy or a renal transplant it is responsible for a large 1 6;2  0(1):8–13 11
population that is affected by this underlying illness.25 Similar
to patients with other chronic diseases, patients with chronic
renal disease have multiple healthcare contacts (including
dialysis) and have multiple previous antibiotic exposures
due to empiric or deﬁnitive treatment of different infectious
diseases complications, including peritonitis resulting from
peritoneal dialysis. Concomitant administration of steroids
occurs frequently when patients have serious comorbidities
and need assistance in the treatment of various complica-
tions.
The clinical features found in our CDI patients included
an increased white blood cell count, elevated serum creati-
nine and reduced serum albumin levels. These ﬁndings are
the basis for most clinical prediction rules used today.18,19,26–29
Patients presenting with severe CDI typically were older and
had an increased number of bowel movements, had a his-
tory of systemic antibiotic use, and presented with fever,
abdominal distention, abnormal respiratory rate, abnormal
level of C-reactive protein, prior episodes of CDI, increased
white blood cell count, elevated serum creatinine level, and
low serum albumin level.18,19,26–29 Using these clinical predic-
tion rules most of our patients had severe CDI.
The use of clinical prediction rules in CDI  are also used
to determine individuals at risk of having poor outcomes or
a relapse.28,30–34 The most prominent factor predictive of a
poor outcome or relapse among CDI patients described in this
report was infection with strain 02735 and chronic renal dis-
ease.
After eliminating confounders, independent risk factors for
CDI included prior use of steroids, previous episodes of pneu-
monia, and prior hospitalizations (Table 2). The epidemiology
of C. difﬁcile infections is constantly changing and probably
explains some of the differences found in our study compared
with previous observations made in Mexico.14,22,36
The diagnosis of CDI was primarily carried out using a com-
mercial PCR kit, a test that has high sensitivity and speciﬁcity
but with several limitations, including the inability of this test
to identify emergent C. difﬁcile variants.9,37,38
The choice for initial empirical therapy in our study
consisted of metronidazole. Other therapeutic choices
included administration of oral vancomycin as opposed to
intravenous administration combined with either intravenous
metronidazole or intravenous tigecycline based on individual
response to oral metronidazole.39,40
In an effort to control the outbreak our intervention pro-
gram focused on identifying CDI cases as quickly as possible,
providing early treatment, isolating CDI cases in a dedicated
ward, and restricting all quinolone use.41–43 The presence of
a disease such as CDI that is transmitted via oral-fecal con-
tamination prompted us to reevaluate patient hand washing
practices prior to each meal or the intake of oral medication,
in addition to assessing hand washing practices of the staff
assigned to help feed patients. This resulted in the implemen-
tation of an aggressive patient hand washing campaign.
All patients discharged after an episode of CDI received
careful instructions on how to proceed should a relapse
occur.44 The instructions included a description of some of
the symptoms that may present during a relapse, where to get
medical attention, and what to inform healthcare personnel
on arrival to clinics.
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The present study had several limitations including the
lack of C. difﬁcile cultures to enable typing, limited use of a
computed tomography scan for abdominal radiographic imag-
ing prior to colonoscopy, colonoscopy for diagnosis of CDI,
follow-up PCR testing was used only in select patients,45 and
no autopsies were performed.
In conclusion, the control of CDI in our hospital now rep-
resents a constant challenge. The control of CDI in a hospital
like ours should include a tailored strategy designed to iden-
tify cases of CDI as rapidly as possible. This study represents
the ﬁrst description of an extended CDI outbreak caused by
diverse C. difﬁcile strains including the NAP1/B1/027 strain in
a Mexican hospital.
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Members for the Hospital Civil de Guadalajara, Fray Anto-
nio Alcalde Clostridium difﬁcile Team were: Leon-Garnica G,
Castillo-Mondragon A, Camacho-Rubio JR, Rodriguez-Nun˜ez
AJ, Mendoza-Mujica C, Heredia-Cervantes J, Mata-Esteban
RA, Llamas-Alonso J, Lucio-Figueroa JO, Macias-Hernandez
KZ, Macías-Bolan˜os DJ. Cardenas-Lara FJ, Fernandez-Ramirez
A (Instituto de Patologia Infecciosa y Experimental, Centro
Universitario Ciencias de la Salud, Universidad de Guadala-
jara), Vazquez-León M,  Gomez-Quiroz P. (Infectious Diseases
Unit Attendings), Eduardo Ortigosa-Medrano, Gomez-Gomez
K, Vargas-Garcia LF (Infectious Diseases Unit Fellows)
Gutierrez-Martinez ES, Garcia-Reyes MG, Zamora-Morales S,
Casillas-Pacheco MA, Martinez-Cardona L, Magan˜a-Ibarra S.
Tello G. (Epidemiology) Rodriguez-Chagollan JJ, Anguiano-
Gaytan G, Atilano-Duran MCG,  Llanos-Perez E, Gomez-Quiroz
A, Zavala M (Microbiology).
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